Background Standard-of-care treatment for patients with newly diagnosed multiple myeloma
includes combination therapies for patients who are not eligible for autologous stem-cell …

Background In the primary analysis of the phase 3 MAIA trial (median follow-up 28· 0
months), a significant improvement in progression-free survival was observed with …

Summary This United States community study evaluated the combination of daratumumab,
bortezomib, cyclophosphamide and dexamethasone (D‐VCd) in newly diagnosed multiple …

PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months),
daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged …

Background In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …

Background Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces
direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy …

Background CASSIOPEIA part 1 showed superior depth of response and significantly
improved progression-free survival with daratumumab, bortezomib, thalidomide, and …

Background Daratumumab showed promising efficacy alone and with lenalidomide and
dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple …

Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …

Immunotherapy is changing the paradigm of multiple myeloma (MM) management and
daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for …